[{"orgOrder":0,"company":"Applied Biology","sponsor":"Hinova","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor||AR","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Hinova","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Hinova"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Kintor Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Biology \/ Applied Biology","highestDevelopmentStatusID":"15","companyTruncated":"Applied Biology \/ Applied Biology"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Kintor Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Biology \/ Applied Biology","highestDevelopmentStatusID":"15","companyTruncated":"Applied Biology \/ Applied Biology"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Corpometria Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"||Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Applied Biology \/ Corpometria Institute","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Corpometria Institute"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Corpometria Institute","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Corpometria Institute","highestDevelopmentStatusID":"1","companyTruncated":"Applied Biology \/ Corpometria Institute"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Safety Shot","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"JW-100","moa":"CB1\/2 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Applied Biology \/ Jupiter Wellness","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Jupiter Wellness"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"AB-101","moa":"PD-L1","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Safety Shot","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pimozide","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Biology \/ Applied Biology","highestDevelopmentStatusID":"1","companyTruncated":"Applied Biology \/ Applied Biology"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Safety Shot","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pimozide","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Jupiter Wellness","highestDevelopmentStatusID":"1","companyTruncated":"Applied Biology \/ Jupiter Wellness"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Applied Biology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ECUADOR","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Dutasteride","moa":"||Steroid 5-alpha-reductase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Applied Biology","highestDevelopmentStatusID":"1","companyTruncated":"Applied Biology \/ Applied Biology"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Complex Science","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CS-001","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Complex Science","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Complex Science"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Follea International | Daniel Alain","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DA-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Applied Biology \/ Follea International | Daniel Alain","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Follea International | Daniel Alain"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Follea International | Daniel Alain","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DA-005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Follea International | Daniel Alain","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Follea International | Daniel Alain"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Daniel Alain | Follea International","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"DA-007","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Daniel Alain | Follea International","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Daniel Alain | Follea International"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Follea International","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Daniel Alain Probiotic","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Follea International","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Follea International"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"DA-OTC-002","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Photocil","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Photocil","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Photocil","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Complex Science","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CS-002","moa":"mTOR","graph1":"Dental and Oral Health","graph2":"Phase I\/ Phase II","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Complex Science","highestDevelopmentStatusID":"7","companyTruncated":"Applied Biology \/ Complex Science"}]
Find Clinical Drug Pipeline Developments & Deals by Applied Biology
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
